Acrivon Therapeutics, Inc. Common Stock ACRV
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Etzer Darout | BMO Capital | 7.92 $ | 27 $ | 19.08 % | 14/11/2024 |
| Etzer Darout | BMO Capital | 8.91 $ | 28 $ | 19.09 % | 16/09/2024 |
| Matthew Biegler | Oppenheimer | 7.26 $ | 18 $ | 10.74 % | 13/08/2024 |
| Matthew Biegler | Oppenheimer | 8.36 $ | 21 $ | 12.64 % | 14/05/2024 |
| Emily Bodnar | H.C. Wainwright | 8.345 $ | 22 $ | 13.66 % | 14/05/2024 |
| Etzer Darout | BMO Capital | 8.51 $ | 25 $ | 16.49 % | 14/05/2024 |
| Joseph Catanzaro | Piper Sandler | 9.2 $ | 30 $ | 20.80 % | 25/04/2024 |
| Silvan Tuerkcan | JMP Securities | 9.5 $ | 17 $ | 7.50 % | 25/04/2024 |
| Emily Bodnar | H.C. Wainwright | 7.185 $ | 20 $ | 12.82 % | 28/03/2024 |
| Joseph Catanzaro | Piper Sandler | 12.5 $ | 25 $ | 12.50 % | 11/12/2022 |